Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), has announced a share buyback plan, indicating that its current trading price does not reflect its intrinsic value or actual business prospects [1] Group 1: Share Buyback Details - The company is authorized to repurchase up to 274 million shares, which represents 10% of the total shares issued as of the date of the annual general meeting, excluding treasury shares [1] - The board has resolved to utilize the buyback authorization to repurchase shares in the open market for a total price of no less than HKD 100 million [1] Group 2: Rationale and Financial Position - The company believes that the proposed share buyback will demonstrate its confidence in its business development prospects [1] - The existing financial resources of the company are deemed sufficient to support the implementation of the proposed share buyback while maintaining a robust financial position [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited - 1 - 1951 * 自願公告 建議於市場上購回股份 本公告乃由錦欣生殖醫療集團有限公司*（「本公司」）自願刊發。 茲提述本公司日期為2025年6月26日的公告，內容有關（其中包括）本公司股東於本公司於 2025年6月26日舉行的股東週年大會（「股東週年大會」）授出的購回本公司股份（「股份」）的 一般授權（「購回授權」）。根據購回授權，本公司獲准於香港聯合交易所有限公司（「聯交 所」）購回最多274,470,604股股份，佔於股東週年大會日期已發行股份（不包括庫存股份） 總數的10%。 本公司認為，股份目前的交易價格並未反映其內在價值或本公司的實際業務前景。因 此，本公司董事會（「董事會」）已議決利用購回授權，以不時在公開市場上按不少於1億港 元的總價格購回股份（「建議股份購回」）。本公司認為，建議股份購回將展現本公司對其 自身業務發展前 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 錦欣生殖醫療集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊 ...

Group 1 - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 6.2985 million shares on November 26, 2025, marking a 0.43% change [1][2] - Over the past five trading days, there have been five days of net increases in holdings, totaling 20.795 million shares [1][2] - In the last 20 trading days, there were 13 days of net increases, amounting to 31.1263 million shares [1][2] Group 2 - As of now, southbound funds hold 1.474 billion shares of Jinxin Reproductive Medicine, representing 53.44% of the company's total issued ordinary shares [1][2] - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment, mainly in China and the United States [2]

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 611,000 shares on November 24, 2025, marking a consistent trend of net increases over recent trading days [1] - Over the past 5 trading days, there has been a cumulative net increase of 11.76 million shares, while in the last 20 trading days, the total net increase reached 12.71 million shares [1] - As of now, southbound funds hold 1.458 billion shares of Jinxin Reproductive Medicine, accounting for 52.84% of the company's total issued ordinary shares [1] Summary by Category Trading Activity - On November 24, 2025, total shares held reached 1.458 billion, with a change of 611,000 shares, reflecting a 0.04% increase [2] - On November 21, 2025, total shares held were 1.457 billion, with a change of 630,000 shares, also a 0.04% increase [2] - On November 20, 2025, total shares held were 1.456 billion, with a change of 3.183 million shares, indicating a 0.22% increase [2] - On November 19, 2025, total shares held were 1.453 billion, with a change of 3.168 million shares, also a 0.22% increase [2] - On November 18, 2025, total shares held were 1.450 billion, with a change of 4.170 million shares, reflecting a 0.29% increase [2] Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 3.168 million shares on November 19, 2025, marking a 0.22% increase in total shares held [1][2] - Over the past five trading days, there have been four days of net increases in holdings, totaling 6.8563 million shares [1] - In the last twenty trading days, there were ten days of net increases, amounting to 9.4968 million shares [1] - As of now, southbound funds hold 1.453 billion shares of Jinxin Reproductive Medicine, representing 52.69% of the company's total issued ordinary shares [1] Company Overview - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin operates mainly in China and the United States, also engaging in the sale of medical consumables and equipment [2]

JINXIN FERTILITY GROUP LIMITED (a company incorporated in the Cayman Islands with limited liability) SHARE SCHEME PREAMBLE 1. DEFINITIONS 1.1 In this Scheme, the following expressions have the following meanings: Acknowledgement Form shall have the meaning as defined in Rule 6.5; Actual Selling Price means the actual price at which the Option Shares or Restricted Shares are sold (net of brokerage, stamp duty, Stock Exchange trading fee, SFC transaction levy and any other applicable costs) on vesting of an A ...

本人╱吾等 （附註 1 ） 地址為 為上述公司股本中每股面值0.00001美元股份 （附註 2 ） 茲委任股東特別大會主席或 （附註 3 ） Jinxin Fertility Group Limited * 1951 適用於將於2025年12月5日舉行的股東特別大會的代表委任表格 股的登記持有人， 地址為 為本人╱吾等的受委代表出席上述公司謹訂於2025年12月5日（星期五）上午十時正假座中國四川省 成都市錦江區畢昇路66號四川錦欣西囡婦女兒童醫院畢昇院區5樓會議室3舉行的股東特別大會（「大 會」）及其任何續會，於大會（及其任何續會）上代表本人╱吾等考慮並酌情通過股東特別大會通告所 載的決議案，並按下列指示 （附註 4 ） 就決議案為本人╱吾等及以本人╱吾等名義進行投票。 | | | （附註5） 普通決議案 | （附註4） 贊成 | 反對 | （附註4） | | --- | --- | --- | --- | --- | --- | | 1. | (i) | 待香港聯合交易所有限公司（「聯交所」）上市委員 | | | | | | | 會批准因根據本公司2025年股份計劃（「2025年股 | | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited * 1951 股東特別大會通告 茲通告錦欣生殖醫療集團有限公司*（「本公司」）謹訂於2025年12月5日（星期五）上午十時 正假座中國四川省成都市錦江區畢昇路66號四川錦欣西囡婦女兒童醫院畢昇院區5樓會議 室3舉行股東特別大會（「大會」），以處理以下事項： 普通決議案 承董事會命 錦欣生殖醫療集團有限公司* * 僅供識別 - 1 - 1. 「動議： (i) 待香港聯合交易所有限公司（「聯交所」）上市委員會批准因根據本公司2025年股 份計劃（「2025年股份計劃」）可能授出的任何股份獎勵及╱或購股權（「獎勵」）歸 屬及╱或獲行使後可能須予發行及配發的本公司股份（「股份」）上市及買賣後， 謹此批准及採納2025年股份計劃，並謹此授權本公司任何董事採取一切可能屬 必要或權宜的行動及訂立一切有關交易、安排及協議，以使2025年股份計劃全 面生效，包 ...

閣下如已售出或轉讓名下所有錦欣生殖醫療集團有限公司*的股份，應立即將本通函交予買主 或承讓人或經手買賣的銀行、股票經紀或其他代理人，以便轉交買主或承讓人。 此乃要件 請即處理 閣下對本通函或應採取的行動如有任何疑問，應諮詢 閣下的股票經紀、銀行經理、律師、專 業會計師或其他專業顧問。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本通函全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 1951 Jinxin Fertility Group Limited (1)建議採納2025年股份計劃 (2)有條件向執行董事授出購股權 (3)建議重選非執行董事 及 (4)股東特別大會通告 錦欣生殖醫療集團有限公司*謹訂於2025年12月5日（星期五）上午十時正假座中國四川省成都 市錦江區畢昇路66號四川錦欣西囡婦女兒童醫院畢昇院區5樓會議室3舉行股東特別大會，召開 大會的通告載於本通函第38至41頁。隨函亦附奉股東特別大會適用的代表委任表格。此代表委 任表格亦刊載於香港聯合交易所有限公司的網站(www.hkexnew ...